SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (14086)2/2/1998 9:08:00 PM
From: Hippieslayer  Read Replies (4) | Respond to of 32384
 
I think LGND is a good short at this level.



To: celeryroot.com who wrote (14086)2/2/1998 9:11:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
I agree that paptent expirations are also a factor. Most of the big pharmas have a relative small number of real blockbusters and losing patent protection on one or two can have a major impact on the bottom line. LLY's Prozac runs out in 2002 and I think another big money maker loses patent protection in 2003. I think that GLX's Zantac also runs out relatively soon.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News